- Home
- CINT vs ANAB Comparison
CINT vs ANAB Comparison
Compare CINT & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CINT
- ANAB
- Stock Information
- Founded
- CINT 1995
- ANAB 2005
- Country
- CINT Brazil
- ANAB United States
- Employees
- CINT N/A
- ANAB N/A
- Industry
- CINT EDP Services
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- CINT Technology
- ANAB Health Care
- Exchange
- CINT Nasdaq
- ANAB Nasdaq
- Market Cap
- CINT 833.8M
- ANAB 759.5M
- IPO Year
- CINT 2021
- ANAB 2017
- Fundamental
- Price
- CINT $5.68
- ANAB $19.20
- Analyst Decision
- CINT Buy
- ANAB Buy
- Analyst Count
- CINT 6
- ANAB 10
- Target Price
- CINT $7.72
- ANAB $36.38
- AVG Volume (30 Days)
- CINT 104.7K
- ANAB 917.7K
- Earning Date
- CINT 03-12-2025
- ANAB 05-08-2025
- Dividend Yield
- CINT N/A
- ANAB N/A
- EPS Growth
- CINT 24.21
- ANAB N/A
- EPS
- CINT 0.19
- ANAB N/A
- Revenue
- CINT $382,840,144.00
- ANAB $91,280,000.00
- Revenue This Year
- CINT $17.20
- ANAB N/A
- Revenue Next Year
- CINT $14.52
- ANAB $70.85
- P/E Ratio
- CINT $29.72
- ANAB N/A
- Revenue Growth
- CINT 6.02
- ANAB 432.03
- 52 Week Low
- CINT $3.34
- ANAB $12.21
- 52 Week High
- CINT $8.04
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- CINT 25.36
- ANAB 60.03
- Support Level
- CINT $6.07
- ANAB $17.35
- Resistance Level
- CINT $6.07
- ANAB $19.82
- Average True Range (ATR)
- CINT 0.19
- ANAB 1.41
- MACD
- CINT -0.04
- ANAB 0.16
- Stochastic Oscillator
- CINT 3.00
- ANAB 71.76
About CINT CI&T Inc
CI&T Inc is engaged in providing strategy, design, and software engineering services to enable digital transformation for companies. The company mainly develops customizable software through the implementation of several software solutions, including Machine Learning, Artificial Intelligence (AI), Analytics, Cloud, and Mobility technologies. The majority of the revenue is generated from the North America and Europe, followed by Asia, Pacific and Japan.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).